Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mucosal Immunol ; 6(4): 728-39, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23149662

ABSTRACT

Studies examining the role of programmed death 1 (PD-1) ligand 2 (PD-L2)/PD-1 in asthma have yielded conflicting results. To clarify its role, we examined the PD-L2 expression in biopsies from human asthmatics and the lungs of aeroallergen-treated mice. PD-L2 expression in bronchial biopsies correlated with the severity of asthma. In mice, allergen exposure increased PD-L2 expression on pulmonary myeloid dendritic cells (DCs), and PD-L2 blockade diminished allergen-induced airway hyperresponsiveness (AHR). By contrast, PD-1 blockade had no impact, suggesting that PD-L2 promotes AHR in a PD-1-independent manner. Decreased AHR was associated with enhanced serum interleukin (IL)-12 p40, and in vitro stimulation of DCs with allergen and PD-L2-Fc reduced IL-12 p70 production, suggesting that PD-L2 inhibits allergen-driven IL-12 production. In our model, IL-12 did not diminish T helper type 2 responses but rather directly antagonized IL-13-inducible gene expression, highlighting a novel role for IL-12 in regulation of IL-13 signaling. Thus, allergen-driven enhancement of PD-L2 signaling through a PD-1-independent mechanism limits IL-12 secretion, exacerbating AHR.


Subject(s)
Asthma/immunology , Asthma/metabolism , Dendritic Cells/immunology , Dendritic Cells/metabolism , Interleukin-12/biosynthesis , Programmed Cell Death 1 Ligand 2 Protein/metabolism , Allergens/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/immunology , Asthma/drug therapy , Asthma/genetics , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/metabolism , Gene Expression Regulation/drug effects , Immunoglobulin G/immunology , Interleukin-12 Subunit p40/metabolism , Interleukin-13/metabolism , Interleukin-13/pharmacology , Male , Mice , Mucus/metabolism , Myeloid Cells/immunology , Myeloid Cells/metabolism , Programmed Cell Death 1 Ligand 2 Protein/agonists , Programmed Cell Death 1 Ligand 2 Protein/antagonists & inhibitors , Signal Transduction/drug effects
2.
Biologicals ; 40(6): 473-81, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22901944

ABSTRACT

During the manufacture of human plasma derivatives, a series of complementary measures are undertaken to prevent transmission of blood-borne viruses. Virus filtration using 15 nm (Planova15N) filters has successfully been implemented in manufacturing processes for various plasma derivatives primarily because virus filtration is a technique, mild for proteins, that can effectively remove even small non-lipid-enveloped viruses, such as HAV and parvovirus B19. However, the use of 15 nm filters has limitations with regard to protein capacity of the filters and the process flow, resulting in an expensive manufacturing step. Therefore, studies were performed to test whether the use of 20 nm (Planova20N) filters, having different characteristics compared to 15 nm filters, can be an alternative for the use of 15 nm filters. It is shown that 20 nm filtration can be an alternative for 15 nm filtration. However, the virus removal capacity of the 20 nm filters depends on the plasma product that is filtered. Therefore, an optimisation study must be performed with regard to process parameters such as pressure, pH and protein concentration for each plasma product. In this study, using optimised conditions, the virus removal capacity of 20 nm filters appears to be comparable or even better when compared to that of 15 nm filters.


Subject(s)
Blood Substitutes , Blood-Borne Pathogens/isolation & purification , Filtration/instrumentation , Viruses/isolation & purification , Complement C1 Inactivator Proteins/analysis , Complement C1 Inhibitor Protein , Immunoglobulin G/analysis , Prothrombin/analysis , Transferrin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...